Iveric bio’s $45 Million Common Stock and Pre-Funded Warrants Offering


Davis Polk advised the sole book-running manager and representative of the several underwriters in connection with a $45 million SEC-registered common stock and pre-funded warrants offering by IVERIC bio. Wilmer Cutler Pickering Hale and Dorr advised IVERIC bio.

IVERIC’s common stock is listed on the Nasdaq Global Select Market under the symbol “ISEE.”

Cowen and Company, LLC and Wedbush Securities Inc. were the underwriters in the offering.

Based in New York and New Jersey, IVERIC is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. IVERIC is currently developing both therapeutic candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases.

The Davis Polk corporate team included partner Richard D. Truesdell Jr. (Picture) and associates Joseph S. Payne and Johnathan M. Nixon. Partner John M. Brandow provided equity derivatives advice. The tax team included counsel Ethan R. Goldman and associate Rachel Lerner. Associate Jay Frankel provided intellectual property and technology advice. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.

Involved fees earner: John Brandow – Davis Polk & Wardwell; Jay Frankel – Davis Polk & Wardwell; Ethan Goldman – Davis Polk & Wardwell; Marcie Goldstein – Davis Polk & Wardwell; Rachel Lerner – Davis Polk & Wardwell; Johnathan Nixon – Davis Polk & Wardwell; Joseph Payne – Davis Polk & Wardwell; Richard Truesdell Jr. – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Cowen and Company;

Print Friendly, PDF & Email
Avatar

Author: Ambrogio Visconti